Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Maze Therapeutics, Inc.MAZE · Entity 1775 | CSBO | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Maze Therapeutics, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,316 |
Ending reported balance
After 2026-09-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-29 · Exercise / conversion · Acquired 7,500 · Balance 39,816 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Row 2 · 2026-09-29 · Sale · Disposed 7,500 · Balance 32,316 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2031-04-11 | Direct | 6,643 |
Reported balance
After 2026-09-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-29 · Exercise / conversion · Disposed 7,500 · Balance 6,643 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Oct 2, 2026 00:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000030 · form4-10012026_081054.xml · derivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,643 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 00:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 7,500 | $27.06 | $202,920.75 |
DisclosureSEC source: 0002050167-26-000030 · form4-10012026_081054.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 00:06 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000030 · form4-10012026_081054.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 36 | $25.81 | $929.16 |
DisclosureSEC source: 0002050167-26-000027 · form4-09042026_080945.xml · nonDerivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,316 F1 · kind: The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 3,207 | $26.01 | $83,424.65 |
DisclosureSEC source: 0002050167-26-000027 · form4-09042026_080945.xml · nonDerivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,352 F1 · kind: The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 391 | $27.12 | $10,604.35 |
DisclosureSEC source: 0002050167-26-000027 · form4-09042026_080945.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,559 F1 · kind: The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 2,800 | $26.38 | $73,852.80 |
DisclosureSEC source: 0002050167-26-000027 · form4-09042026_080945.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,950 F1 · kind: The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:29 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002050167-26-000025 · form4-09032026_080935.xml · derivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:29 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002050167-26-000025 · form4-09032026_080935.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 22:32 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000023 · form4-08312026_100823.xml · derivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,143 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 22:32 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 7,500 | $27.58 | $206,823.75 |
DisclosureSEC source: 0002050167-26-000023 · form4-08312026_100823.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $28.01 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 22:32 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000023 · form4-08312026_100823.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000019 · form4-07312026_080715.xml · derivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,643 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 400 | $27.89 | $11,156.00 |
DisclosureSEC source: 0002050167-26-000019 · form4-07312026_080715.xml · nonDerivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.81 to $27.96 per share, inclusive. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 7,100 | $27.31 | $193,875.44 |
DisclosureSEC source: 0002050167-26-000019 · form4-07312026_080715.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,650 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $27.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000019 · form4-07312026_080715.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:17 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000016 · form4-07012026_080715.xml · derivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,143 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:17 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 7,500 | $28.02 | $210,150.00 |
DisclosureSEC source: 0002050167-26-000016 · form4-07012026_080715.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:17 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000016 · form4-07012026_080715.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · balance_after: The reported total includes 1,442 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000013 · form4-06022026_080603.xml · derivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,643 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 7,500 | $26.34 | $197,553.75 |
DisclosureSEC source: 0002050167-26-000013 · form4-06022026_080603.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,808 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.64 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000013 · form4-06022026_080603.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,985 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000010 · form4-05062026_080545.xml · derivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,725 Underlying: Common Stock · 5,985 shares Expires 2033-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,320 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000010 · form4-05062026_080545.xml · derivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,204 Underlying: Common Stock · 8,320 shares Expires 2032-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 5,985 | $10.42 | $62,363.70 |
DisclosureSEC source: 0002050167-26-000010 · form4-05062026_080545.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 8,320 | $10.42 | $86,694.40 |
DisclosureSEC source: 0002050167-26-000010 · form4-05062026_080545.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:18 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000008 · form4-05012026_080517.xml · derivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,143 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:18 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 7,500 | $25.37 | $190,299.00 |
DisclosureSEC source: 0002050167-26-000008 · form4-05012026_080517.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,503 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.08 to $25.77 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:18 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000008 · form4-05012026_080517.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000006 · form4-04012026_080428.xml · derivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,643 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 790 | $30.02 | $23,713.67 |
DisclosureSEC source: 0002050167-26-000006 · form4-04012026_080428.xml · nonDerivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,503 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.87 to $30.24 per share, inclusive. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 6,710 | $29.26 | $196,305.08 |
DisclosureSEC source: 0002050167-26-000006 · form4-04012026_080428.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,293 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.86 to $29.84 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 20:12 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000006 · form4-04012026_080428.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantRestricted Stock Units · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002050167-26-000005 · form4-03032026_090337.xml · derivative · entry 6 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. F8 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $45.61 | $0.00 |
DisclosureSEC source: 0002050167-26-000005 · form4-03032026_090337.xml · derivative · entry 5 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2036-03-01 F5 · derivative.exercise_date: The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000005 · form4-03032026_090337.xml · derivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,143 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 3,761 | $45.72 | $171,967.21 |
DisclosureSEC source: 0002050167-26-000005 · form4-03032026_090337.xml · nonDerivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,503 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.02 per share, inclusive. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 3,739 | $45.13 | $168,756.03 |
DisclosureSEC source: 0002050167-26-000005 · form4-03032026_090337.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,264 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000005 · form4-03032026_090337.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:21 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-26-000003 · form4-02022026_090232.xml · derivative · entry 5 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,643 Underlying: Common Stock · 7,500 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:21 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 2,800 | $45.01 | $126,022.40 |
DisclosureSEC source: 0002050167-26-000003 · form4-02022026_090232.xml · nonDerivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,503 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:21 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 3,500 | $44.04 | $154,146.65 |
DisclosureSEC source: 0002050167-26-000003 · form4-02022026_090232.xml · nonDerivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,303 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:21 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 1,200 | $43.18 | $51,821.28 |
DisclosureSEC source: 0002050167-26-000003 · form4-02022026_090232.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,803 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:21 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 7,500 | $10.42 | $78,150.00 |
DisclosureSEC source: 0002050167-26-000003 · form4-02022026_090232.xml · nonDerivative · entry 1 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-25-000007 · form4-12312025_091220.xml · derivative · entry 7 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,143 Underlying: Common Stock · 100 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 100 | $40.36 | $4,036.00 |
DisclosureSEC source: 0002050167-25-000007 · form4-12312025_091220.xml · nonDerivative · entry 5 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,503 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 30, 2025 Filed Dec 31, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionCommon Stock | 100 | $10.42 | $1,042.00 |
DisclosureSEC source: 0002050167-25-000007 · form4-12312025_091220.xml · nonDerivative · entry 4 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Exercise / conversionStock Option (Right to Buy) · Derivative | 72,400 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0002050167-25-000007 · form4-12312025_091220.xml · derivative · entry 6 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,243 Underlying: Common Stock · 72,400 shares Expires 2031-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F5 · derivative.exercise_date: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 6,035 | $41.13 | $248,211.10 |
DisclosureSEC source: 0002050167-25-000007 · form4-12312025_091220.xml · nonDerivative · entry 3 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,503 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.99 to $41.51 per share, inclusive. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 66,365 | $40.51 | $2,688,552.33 |
DisclosureSEC source: 0002050167-25-000007 · form4-12312025_091220.xml · nonDerivative · entry 2 Dandekar Atul · CIK 0002050167 · CSBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,538 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.99 to $40.985 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.